期刊文献+

慢性丙型肝炎患者治疗前后血清中IL-18、IFN-γ及IL-4的表达及意义

The expression of IL-18, IFN-γ and IL-4 in the serum of patients with chronic hepatitis C before and after therapy
原文传递
导出
摘要 目的:研究慢性丙型肝炎患者治疗前后血清中白介素-18(IL-18)、干扰素-γ(IFN-γ)及白介素-4(IL-4)的表达情况,探讨IL-18、IFN-γ在及IL-4在慢性丙型肝炎发病中的作用及可能临床意义。方法:酶联免疫吸附法(ELISA)检测20例正常人,42例慢性丙型肝炎患者治疗前后血清中IL-18、IFN-γ在及IL-4水平。结果慢性丙型肝炎患者血清IL-18表达高于健康对照组(380.3±27.2pg/mlvs104.1±10.9pg/ml,P<0.05),血清IFN-γ表达也高于健康对照组(3.2±0.4IU/mlvs1.2±0.2IU/ml,P<0.05),而慢性丙型肝炎患者与健康对照组间IL-4表达无统计学差异(23.8±2.7pg/mlvs23.5±2.9pg/ml,P>0.05)。慢性丙型肝炎患者血清IL-18表达与谷丙转氨酶具有正相关性(r1=0.701,P<0.05);IFN-γ表达与谷丙转氨酶均具有正相关性(r2=0.629,P<0.05)。治疗前慢性丙型肝炎患者应对组血清中IL-18及IFN-γ表达高于无应答组(380.3±27.2pg/mlvs280.1±19.8pg/ml,P<0.05)(3.7±0.4IU/mlvs2.9±0.2IU/ml,P<0.05)。治疗后慢性丙型肝炎患者应答组血清中IL-18及IFN-γ表达较治疗前下调(380.3±27.2pg/mlvs150.6±11.4pg/ml,P<0.05)(3.7±0.4IU/mlvs1.8±0.1IU/ml,P<0.05),治疗后无应答组血清中IL-18及IFN-γ表达较治疗前无统计学差异(280.1±19.8pg/mlvs250.6±24.7pg/ml,P>0.05)(2.9±0.2IU/mlvs2.6±0.5IU/ml,P>0.05),而有无应答组间IL-4在治疗前后均无统计学差异(P>0.05)。结论:慢性丙型肝炎患者中,IL-18及IFN-γ表达增高,IL-4差异无统计学意义,且IL-18及IFN-γ表达与谷丙转氨酶水平有关。IL-18及IFN-γ可能在慢性丙型肝炎的发生发展、预测干扰素联合利巴韦林抗病毒疗效中有一定临床指导意义。 Objective:To explore the relationship between cytokines (IL- 18, IFN-γ , IL-4) and pathogenesis of chronic hepatitis C, we investigate the expression of interlukin-18(IL-18), Interferon-gamma(IFN-γ ) and interlukin-4(IL-4) in patients with chronic hepatitis C before and after therapy. Methods:Enzyme-linked immunosorbant assay (ELISA) was used to measure the expression of IL-18 in the serum of 42 patients with chronic hepatitis C and 20 health individuals. Results:Patients of chronic hepatitis C showed higher levels of IL-18 and IFN-γ than the controls (380.3±27.2 pg/ml vs 104.1±10.9 pg/ml, P〈0.05) (3.2±0.4 IU/ml vs 1.2±0.2 IU/ml, P〈0.05), The expression of IL-18 and IFN-γ in patients with chronic hepatitis C was positively related with the expression of alanine aminotransferase (rl=0.701 ,P〈0.05; r2=0.629,P〈0.05). Before the therapy the level of IL-18 and IFN-V in the response group were higher than that in the non-response group(380.3± 27.2 pg/ml vs 280.1± 19.8 pg/ml, P〈0.05) ( 3.7±0.4 tU/ml vs 2.9±0.2 IU/ml, P〈 0.05). After the therapy with Interferon-alpha and ribavirin, the level of IL-18 and IFN-18 decreased significantly in the response group (380.3±27.2 pg/ml vs 150.6±11.4 pg/ml, P〈0.05)(3.7±0.4 IU/ml vs 1.8± 0.1 IU/ml, P〈0.05), but not in the non-response group (P 〉0.05). The level of IL-4 showed no significant change (P 〉 0.05). Conclusions:The IL-18 and IFN-γ is increased in patients with chronic hepatitis C, and may play a role in the pathogenesis and progress of chronic hepatitis C.
出处 《现代生物医学进展》 CAS 2010年第5期906-909,共4页 Progress in Modern Biomedicine
关键词 IL-18 IFN-Γ IL-4 丙型肝炎 IL-18 IFN-γ 1L-4 chronic hepatitis C
  • 相关文献

参考文献13

  • 1Bouzgarrou N, Hassen E, Schvoerer E, et al. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection [J]. J Med Virol, 2008, 80(4): 607-614.
  • 2Gigi E, Raptopoulou-Gigi M, Kalogeridis A, et al. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease [J]. J Viral Hepat,2008,15 (2): 145-154.
  • 3Falasca K, Ucciferri C, Dalessandro M, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C [J]. Ann Clin Lab Sci,2006,36(2): 144-150.
  • 4Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces 1FN-gamma production by T cells [J]. Nature,1995,378 (6552): 88-91.
  • 5Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis [J]. Immunology, 2009, 128(1 Suppl): e514-522.
  • 6Vecchiet J, Falasca K, Cacciatore P, et al. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease [J]. Ann Clin Lab Sci, 2005.35(4): 415-422.
  • 7Ishii K, Sumino Y, Shinohara M, et al. Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C [J]. Hepatol Res,2006,34(1): 15-22.
  • 8Satake S, Nagaki M, Kimura K, et al. Significant effect of hepatitis C virus specific CTLs on viral clearance in patients with type C chronic hepatitis treated with antiviral agents [J]. Hepatol Res,2008,38 (5): 491-500.
  • 9Murata K, Yamamoto N, Kawakita T, et al. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C [J]. Hepatogastroenterology,2005,52(62): 547-551.
  • 10YingLi H, Shumei L, Qian Y, Tianyan C, Yingren Z, Wei C. Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha [J]. Clin Exp Med,2009, 9(2): 173-178.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部